

Sugemalimab: safe and effective consolidation therapy for patients with unresectable Stage III NSCLC

August 8 2022

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

Sugemalimab is a full-length, fully human IgG4 monoclonal antibody targeting PD-L1. GEMSTONE-301 is an ongoing phase 3 trial to evaluate sugemalimab as a consolidation treatment in patients with unresectable stage III [non-small cell lung cancer](#) without [disease progression](#) following chemoradiotherapy. The trial is the first phase 3 study in this setting to include patients who received either concurrent or sequential chemoradiotherapy. Previously, in the pre-planned progression-free survival interim analysis, sugemalimab showed a statistically significant and clinically meaningful improvement in progression-free survival compared with placebo (Lancet Oncol. 2022 Feb;23(2):209-219).

To follow up on this previous work, Yi-Long Wu, M.D., from Guangdong Provincial People's Hospital, in Guangzhou, China and colleagues finished a pre-planned progression-free survival final analysis.

Patients were stratified by ECOG PS (0 vs 1), chemoradiotherapy type (cCRT vs sCRT), and total radiotherapy dose (

Citation: Sugemalimab: safe and effective consolidation therapy for patients with unresectable Stage III NSCLC (2022, August 8) retrieved 19 November 2023 from <https://medicalxpress.com/news/2022-08-sugemalimab-safe-effective-therapy-patients.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.